Immutep Limited is paving the way for innovative cancer treatment with their proprietary soluble LAG-3 protein and MHC Class II agonist, Eftilagimod Alfa (efti). Efti stimulates both innate and adaptive immunity, activating a range of immune cells crucial for fighting cancer. This first-in-class antigen presenting cell (APC) activator has shown promise in the treatment of solid tumors like non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). With its favorable safety profile, Efti is being evaluated in various combinations, including with anti-PD-[L]1 immunotherapy and chemotherapy.
Immutep’s recent announcement of the upcoming poster presentation for the pivotal TACTI-004 Phase III trial highlights the potential of Eftilagimod Alfa in combination with KEYTRUDA® and chemotherapy as first-line therapy for advanced or metastatic NSCLC patients. This trial, set to enroll approximately 750 patients in over 25 countries, has the potential to change the treatment paradigm for NSCLC patients, irrespective of their PD-L1 expression. Immutep’s dedication to developing novel immunotherapies for cancer and autoimmune diseases positions them as a key player in the biotechnology industry, aiming to bring innovative treatment options to patients in need and maximize value for shareholders.
Tags: dendritic cells
Read more from finance.yahoo.com